Published in Br Heart J on March 01, 1983
Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J (Clin Res Ed) (1986) 1.87
Raised concentrations of glucose and adrenaline and increased in vivo platelet activation after myocardial infarction. Br Heart J (1988) 0.86
Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J (1993) 0.79
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet (1981) 4.75
Estimation of infarct size in man and its relation to prognosis. Circulation (1972) 4.19
One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J (Clin Res Ed) (1982) 2.39
Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet (1980) 2.00
Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study. Br Med J (1975) 1.76
Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation (1978) 1.68
Value of electrocardiogram in predicting and estimating infarct size in man. Br Heart J (1979) 1.18
Acute myocardial infarct size estimated by serum CK-MB determinations: clinical accuracy and prognostic relevance utilizing a practical modification of the isoenzyme approach. Am Heart J (1981) 1.05
Quantification of serum creatine phosphokinase isoenzyme activity. Am J Cardiol (1974) 1.05
Limitation of myocardial infarct size in patients less than 66 years treated with alprenolol. Br Heart J (1981) 1.00
An easy and reliable estimation of acute myocardial infarct size from serum CK-MB measurements. Eur J Cardiol (1980) 0.89
Hemodynamic effects of the cardioselective beta-blocking agent metoprolol in acute myocardial infarction. A 24-hour catheterization study. Acta Med Scand (1978) 0.87
The effect of propranolol on canine myocardial CPK distribution space and rate of disappearance. Circulation (1977) 0.85
Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother (1968) 14.80
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol (1993) 10.87
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother (1965) 4.71
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol (1988) 4.35
A 10-year survey of eye injuries in Northern Ireland, 1967-76. Br J Ophthalmol (1980) 4.29
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
The pharmacology of beta sympathetic blockade. Am J Cardiol (1966) 3.96
Carbonated soft drink consumption and bone mineral density in adolescence: the Northern Ireland Young Hearts project. J Bone Miner Res (2003) 3.84
A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer (1971) 3.71
The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM (1996) 3.31
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Optical isomers of propranolol. Nature (1966) 3.09
Surveillance of endophthalmitis following cataract surgery in the UK. Eye (Lond) (2004) 3.07
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
Staffing in cardiology in the United Kingdom 1988. Fifth biennial survey. Br Heart J (1989) 2.93
The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). Cancer (1970) 2.82
The treatment of Wilms' tumor: Results of the national Wilms' tumor study. Cancer (1976) 2.80
Bacteriocin production by Clostridium acetobutylicum in an industrial fermentation process. Appl Environ Microbiol (1979) 2.67
Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet (1971) 2.65
The clinical pharmacology of mexiletine. Br J Clin Pharmacol (1978) 2.56
Presumed infectious endophthalmitis following cataract surgery in the UK: a case-control study of risk factors. Eye (Lond) (2006) 2.56
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog. Br J Pharmacol Chemother (1966) 2.52
Cardio-selective beta-blockade. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 2.33
Mobile coronary care and community mortality from myocardial infarction. Lancet (1985) 2.27
Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment. Cancer Invest (1983) 2.16
The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol (1972) 2.11
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol (1989) 1.92
National Poisons Information Services: report and comment 1980. Br Med J (Clin Res Ed) (1981) 1.91
Oral mexiletine in high-risk patients after myocardial infarction. Lancet (1981) 1.91
The peripheral vascular effects of propranolol and related compounds. Br J Pharmacol Chemother (1967) 1.87
Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst (1983) 1.85
The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide. Br J Pharmacol (1970) 1.81
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Blood cholesterol: is population screening warranted in the UK? Lancet (1989) 1.76
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet (1973) 1.68
Some pharmacological properties of a new adrenergic beta-receptor antagonist. Nature (1966) 1.66
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
The Mediterranean diet revisited--towards resolving the (French) paradox. QJM (2000) 1.61
Effect of propranolol on arrhythmias following coronary artery occlusion in dogs. Cardiovasc Res (1967) 1.61
Anencephalus and spina bifida in Belfast (1964-1968). Ulster Med J (1973) 1.61
Neonatal thyrotoxicosis treated with propranolol. Arch Dis Child (1974) 1.59
Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol (1980) 1.57
Practolol in acute myocardial infarction. Acta Med Scand Suppl (1976) 1.57
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
Stimulation of adrenergic beta-receptors by orciprenaline. Br Med J (1967) 1.52
A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med (1977) 1.51
Staffing in cardiology in the United Kingdom 1990. Sixth biennial survey: with data on facilities in cardiology in England and Wales 1989. Br Heart J (1991) 1.48
Anencephalus in Belfast. Incidence and secular and seasonal variations, 1950-66. Br J Prev Soc Med (1970) 1.48
Prognostic factor in neuroblastoma. Cancer (1987) 1.47
Pre-hospital coronary care and coronary fatality in the Belfast and Glasgow MONICA populations. Int J Epidemiol (2005) 1.47
Debendox and congenital malformations in Northern Ireland. Br Med J (1980) 1.46
A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb (1992) 1.45
Mobile coronary care. Br Heart J (1972) 1.39
Distribution of lipid variables in subjects in Belfast, Northern Ireland and Taiyuan, P R China. Atherosclerosis (1993) 1.39
Clinical pharmacology methodology: introduction. Br J Clin Pharmacol (1978) 1.39
Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am J Ophthalmol (1971) 1.37
Coronary risk factors in schoolchildren. Arch Dis Child (1993) 1.37
Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine. J Pharm Pharmacol (1973) 1.36
The epidemiology of disease expenses. The costs of caring for children with cancer. JAMA (1985) 1.35
Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A (2000) 1.33
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol (1982) 1.32
Recurrence rates of neural tube defects in Dublin maternity hospitals. Ir Med J (1983) 1.32
Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J (1995) 1.31
Mortality of flax workers. Br J Ind Med (1982) 1.30
Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol (1999) 1.30
Mobile coronary care. Lancet (1970) 1.29
Propranolol and iodine-131 in the management of thyrotoxicosis. Lancet (1968) 1.29
Factors associated with anencephalus and spina bifida in Belfast. Br J Prev Soc Med (1973) 1.27
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
Stimulation of gastrin release by catecholamines. Lancet (1972) 1.26
Effects of chemotherapy on the central nervous system. A study of parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood. Cancer (1976) 1.25
Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr (1976) 1.25
Comparison of the effects of propranolol and MJ 1999 on cardiac beta-adrenoceptors in man. Br J Pharmacol (1970) 1.24
Season and outdoor ambient temperature: effects on birth weight. Obstet Gynecol (2000) 1.24
A review of 17 IV-S neuroblastoma patients at the children's hospital of philadelphia. Cancer (1980) 1.23
Respiratory disability in ex-flax workers. Br J Ind Med (1986) 1.23
Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol. Clin Pharmacol Ther (1981) 1.23
Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol (2001) 1.20
Fitness, fatness, and coronary heart disease risk in adolescents: the Northern Ireland Young Hearts Project. Med Sci Sports Exerc (2001) 1.20
Deaths from ischaemic heart disease in Belfast. Br Heart J (1986) 1.18
Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. Br J Pharmacol (1988) 1.17
Anencephalus in the British Isles. Dev Med Child Neurol (1970) 1.17
Major central nervous system malformations notified in Northern Ireland 1964-1968. Dev Med Child Neurol (1972) 1.17
Cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man. Br J Clin Pharmacol (1983) 1.16
Wilm's tumor: an update. Cancer (1980) 1.16
Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest (1991) 1.15
Asthma mortality and death certification in Northern Ireland. Thorax (1994) 1.13
High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res (1999) 1.13